There were some problems in the clinical applications of the IDH inhibitors in AML patients with mutations, such as primary and acquired resistance, although IDH inhibitors could provide in these patients an average survival time of 18–21 months [87]. This evidence concerns the gene IDH2 and acute myeloid leukemia.